BridgeBio files for $225M initial public offering
The company, which builds subsidiary companies centered around genetically driven diseases, said it would trade on the Nasdaq under the ticker symbol BBIO.
Adrenas
The company, which builds subsidiary companies centered around genetically driven diseases, said it would trade on the Nasdaq under the ticker symbol BBIO.